IMM — ImmuPharma Income Statement
0.000.00%
Last trade - 00:00- £12.14m
- £11.91m
Annual income statement for ImmuPharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.127 | 0.118 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.72 | 6.71 | 3.03 | 3.06 | 2.68 |
| Operating Profit | -5.59 | -6.59 | -3.03 | -3.06 | -2.68 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.25 | -8.94 | -4.46 | -3.42 | -2.78 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.86 | -8.17 | -3.81 | -2.92 | -2.48 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.86 | -8.17 | -3.81 | -2.92 | -2.48 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.86 | -8.17 | -3.81 | -2.92 | -2.48 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.034 | -0.029 | -0.013 | -0.008 | -0.005 |